Bivalirudin Infusion for Ventricular Infarction Limitation

Trial Profile

Bivalirudin Infusion for Ventricular Infarction Limitation

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Apr 2018

At a glance

  • Drugs Bivalirudin (Primary) ; Heparin
  • Indications Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms BIVAL
  • Sponsors The Medicines Company
  • Most Recent Events

    • 21 Jul 2016 The trial was completed in Netherlands.
    • 20 Apr 2016 Planned End Date changed from 1 Jun 2016 to 1 Sep 2016.
    • 20 Apr 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jun 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top